PremiumCompany AnnouncementsUpstream Bio Advances Verekitug in Clinical Trials Upstream Bio, Inc.: Strong Buy Rating Driven by Promising Drug Progress and Solid Financial Position Upstream Bio reports Q1 revenue $566k, consensus $326.25k PremiumThe FlyUpstream Bio reports Q4 revenue $613k, consensus $384.75k Upstream Bio appoints Amrbose as General Counsel Upstream Bio to be added to Russell 2000 Index PremiumThe FlyUpstream Bio initiated with an Outperform at William Blair Upstream Bio initiated with an Overweight at Piper Sandler Upstream Bio initiated with an Overweight at JPMorgan 
